

# Togo

Population 2016

7.6 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.32 (0.21–0.44)	4.1 (2.8–5.8)
Mortality (HIV+TB only)	0.17 (0.12–0.22)	2.2 (1.6–2.9)
Incidence (includes HIV+TB)	3.5 (2.8–4.2)	46 (37–56)
Incidence (HIV+TB only)	0.77 (0.5–1.1)	10 (6.5–14)
Incidence (MDR/RR-TB)**	0.11 (0.023–0.2)	1.5 (0.3–2.7)

Estimated TB incidence by age and sex (thousands)\*, 2016

	0-14 years	> 14 years	Total
Females	0.14 (0.11–0.17)	1.3 (1–1.5)	1.4 (1.1–1.7)
Males	0.16 (0.13–0.2)	1.9 (1.5–2.3)	2.1 (1.7–2.5)
Total	0.31 (0.24–0.37)	3.2 (2.6–3.8)	3.5 (2.8–4.2)

TB case notifications, 2016

Total cases notified	2 849
Total new and relapse	2 755
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	99%
- % pulmonary	86%
- % bacteriologically confirmed among pulmonary	92%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	79% (65–97)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.14 (0.1–0.19)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	620	22%
- on antiretroviral therapy	572	92%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			70 (12–130)
Estimated % of TB cases with MDR/RR-TB	2.6% (0.1–5.1)	5.4% (2.6–9.7)	
% notified tested for rifampicin resistance	5%	55%	236
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 11, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 10, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New cases registered in 2015	86%	2 526
Previously treated cases registered in 2015	80%	145
HIV-positive TB cases registered in 2015		
MDR/RR-TB cases started on second-line treatment in 2014	100%	1
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	32% (29–35)

TB financing, 2017

National TB budget (US\$ millions)	2.6
Funding source: 12% domestic, 88% international, 0% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New cases  
— Previously treated cases  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

